Status:
COMPLETED
Updated Severity and Prognosis Score of Pulmonary Alveolar Proteinosis
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Conditions:
Pulmonary Alveolar Proteinosis
Eligibility:
All Genders
18+ years
Brief Summary
By updating the chest HRCT scoring criteria of patients with pulmonary alveolar proteinosis, a new and more perfect system for evaluating the severity of alveolar proteinosis will be established.
Detailed Description
In past, investigators summarized a method that was the severity and prognosis of pulmonary alveolar proteinosis (SPSP) to assess the severity and prognosis of patients with autoimmune pulmonary alveo...
Eligibility Criteria
Inclusion
- The patients had be diagnosed with autoimmune pulmonary alveolar proteinosis through pathology or bronchial alveolar lavage fluid (BALF).
- The patients are old than 18 year.
- .Every patient had a complete medical history, chest HRCT, pulmonary function and arterial blood gas analysis.
- The patients have high level antibody of GM-CSF in serum or BALF.
Exclusion
- The patients had a congenital or secondary pulmonary alveolar proteinosis.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
231 Patients enrolled
Trial Details
Trial ID
NCT04516577
Start Date
January 1 2020
End Date
December 31 2021
Last Update
March 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai pulmonary hospital
Shanghai, Shanghai Municipality, China, 200433